Background/Aim: Chemoradiotherapy (CRT) with high-dose cisplatin has become the
standard of care for larynx preservation in patients with locally advanced squamous cell …

Background/Aim: Pembrolizumab exhibits anticancer efficacy in platinum-sensitive or
platinum-unfit patients with recurrent/metastatic squamous cell carcinoma of the head and …

Poor solubility is a major challenge for enhancing the oral bioavailability and clinical
application of many drugs, including the broad-spectrum chemotherapy drug paclitaxel …

Head and neck cancer (HNC) is the sixth most common cancer worldwide and show low
survival rates and drug resistance, which can be due to the presence of cancer stem cells …

Background/Aim: The implementation of a platinum-containing regimen is recommended for
definitive and adjuvant therapy of patients with locally advanced head and neck tumour. We …

Background Immune checkpoint inhibitors (ICIs) are essential in treating recurrent/metastatic
squamous cell carcinoma of the head and neck (R/M SCCHN). However, the overall …

Abstract Background/Aim: The advent of immune checkpoint inhibitor (ICI) treatment has
transformed the treatment of recurrent or metastatic head and neck cancer; however …

Background/Aim: Prior immune-checkpoint inhibitors, weekly paclitaxel-cetuximab was one
of the few options for platinum-ineligible patients with recurrent/metastatic squamous cell …

Purpose: In the present study, to achieve high paclitaxel (PTX) loading in a conjugated drug
delivery system with minimal long-term side effects, we formulated a novel degradable …